
Septerna Inc (SEPN) Stock Forecast & Price Target
Septerna Inc (SEPN) Analyst Ratings
Bulls say
Septerna is a clinical-stage biotechnology company with a strong pipeline in endocrinology, immunology and inflammation, and metabolic disease. Key recent developments have been the discontinuation of their Ph2b CSU study of their MRGPRX2 inhibitor, EVO756, which did not meet primary endpoint, and the initiation of a Phase 1 trial for their potent oral small molecule PTH1R agonist for hypoparathyroidism, SEP-479. Risks include potential delays in R&D or commercial development and the emergence of surprise competitors. However, with increasing physician and patient enthusiasm for novel PTH treatments and the potential for once-daily dosing with SEP-479, the company has upside potential and a BUY rating.
Bears say
Septerna is a clinical-stage biotechnology company with a shaky track record, evidenced by their recent competitor failures and their own struggles with CSU trials. They are heavily reliant on their proprietary Native Complex Platform, which has yet to yield any successful drugs on the market. Additionally, their financial outlook is not promising, with a projected revenue of only $0.74B in 2040 and a high risk of dilution for investors.
This aggregate rating is based on analysts' research of Septerna Inc and is not a guaranteed prediction by Public.com or investment advice.
Septerna Inc (SEPN) Analyst Forecast & Price Prediction
Start investing in Septerna Inc (SEPN)
Order type
Buy in
Order amount
Est. shares
0 shares